| Drug | Indication | Topic |
|---|---|---|
| Evomela (melphalan) For Injection | Multiple Melanoma | To evaluate the efficacy and safety of Evomela for maintenance treatment of Multiple Melanoma |
| Drug | Indication | Topic |
|---|---|---|
| CID-103 | Multiple Melanoma | To evaluate the efficacy and safety of CID-103 for treatment of Multiple Melanoma |
For more information on trials conducted by our partners for CNCT19 and BI-1206, please refer to clinicaltrials.gov.
CASI Pharmaceuticals, Inc. is a NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products. CASI has built a portfolio that includes approved and investigational assets. We conduct our commercial, clinical operations and R&D activities through our subsidiaries in China and branch office in Rockville, Maryland.
EVOMELA® (melphalan) for Injection is proprietary to Acrotech Biopharma LLC and its affiliates.
© 2023 CASI Pharmaceuticals Inc.
All Rights Reserved.